• Product NameEVER1 Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAffinity chromatography purified via peptide column
• ApplicationsELISA WB IHC
• Species ReactivityHu Ms
• SpecificityAt least four isoforms of EVER1 are known to exist. This EVER1 antibody does not cross-react with EVER2.
• Immunogen TypePeptide
• Immunogen DescriptionRaised against a 15 amino acid peptide from near the center of human EVER1.
• Target NameEVER1
• Alternative Names    EV1, EVIN1, Transmembrane protein channel-like protein 6, TMC6
• Accession No. Swiss-Prot:Q7Z403
  Gene ID:11322
• UniprotQ7Z403
• Gene ID11322;
• Concentration 1mg/ml
• Formulation Supplied in PBS containing 0.02% sodium azide.
• Storage Can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Epidermodysplasia verruciformis (EV) is an autosomal recessive dermatosis characterized by abnormal susceptibility to human papillomaviruses (HPVs) and a high rate of progression to squamous cell carcinoma on sun-exposed skin. EV is caused by mutations in either of two adjacent genes, EVER1 and EVER2, located on chromosome 17q25.3. Both of these genes encode integral membrane proteins that localize to the endoplasmic reticulum and are predicted to form transmembrane channels. Both EVER1 and EVER2 are members of the transmembrane channel-like (TMC) protein family. EVER1 possesses eight trans-membrane domains and two leucine zipper motifs. EVER1 and EVER2 form a complex and interact with the zinc transporter 1 (ZnT-1), suggesting that EVER1 and EVER2 act to regulate cellular zinc balance.

• Western blot analysis of EVER1 in human spleen tissue lysate with EVER1 antibody at (A) 1 and (B) 2 ug/mL.
• Immunohistochemistry of EVER1 in human spleen with EVER1 antibody at 2.5 ug/mL.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting